Freja K. Ekman

Freja K. Ekman

Auto-generated profile, based on publicly available information

Freja K. Ekman

Stanford University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
TGThomas Gaj
Thomas Gaj
DODavid S. Ojala
David S. Ojala
FEFreja K. Ekman
Freja K. Ekman
LBLeah C. Byrne
Leah C. Byrne
PLPrajit Limsirichai
Prajit Limsirichai
DSDavid Schaffer
David Schaffer
CRISPR-Cas9–mediated genome editing can be used to treat ALS in an animal model of the disease.

1 September 2019 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
FEFreja K. Ekman
Freja K. Ekman
DODavid S. Ojala
David S. Ojala
MAMaroof M. Adil
Maroof M. Adil
PLPaola A. Lopez
Paola A. Lopez
DSDavid Schaffer
David Schaffer
TGThomas Gaj
Thomas Gaj
Huntington's disease (HD) is a currently incurable and, ultimately, fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion within exon 1 of the huntingtin (HTT) gene, which results in the production of a mutant protein that forms inclusions and selectively destroys neurons in the striatum and other adjacent structures. The RNA-guided Cas9 endonuclease from CRISPR-Cas9 systems is a versatile technology for inducing DNA double-strand breaks that can stimulate the introduction of frameshift-inducing mutations and permanently disable mutant gene function. Here, we show that the Cas9 nuclease from Staphylococcus aureus, a small Cas9 ortholog that can be packaged alongside a single guide RNA into a single adeno-associated virus (AAV) vector, can be used to disrupt the expression of the mutant HTT gene in the R6/2 mouse model of HD following its in vivo delivery to the striatum. Specifically, we found that CRISPR-Cas9-mediated disruption of the mutant HTT gene resulted in a ∼50% decrease in neuronal inclusions and significantly improved lifespan and certain motor deficits. These results thus illustrate the potential for CRISPR-Cas9 technology to treat HD and other autosomal dominant neurodegenerative disorders caused by a trinucleotide repeat expansion via in vivo genome editing.

2 March 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TGThomas Gaj
Thomas Gaj
BSBrett T. Staahl
Brett T. Staahl
GRGonçalo M. C. Rodrigues
Gonçalo M. C. Rodrigues
PLPrajit Limsirichai
Prajit Limsirichai
FEFreja K. Ekman
Freja K. Ekman
DSDavid Schaffer
David Schaffer
Realizing the full potential of genome editing requires the development of efficient and broadly applicable methods for delivering programmable nucleases and donor templates for homology-directed repair (HDR). The RNA-guided Cas9 endonuclease can be introduced into cells as a purified protein in complex with a single guide RNA (sgRNA). Such ribonucleoproteins (RNPs) can facilitate the high-fidelity introduction of single-base substitutions via HDR following co-delivery with a single-stranded DNA oligonucleotide. However, combining RNPs with transgene-containing donor templates for targeted gene addition has proven challenging, which in turn has limited the capabilities of the RNP-mediated genome editing toolbox. Here, we demonstrate that combining RNP delivery with naturally recombinogenic adeno-associated virus (AAV) donor vectors enables site-specific gene insertion by homology-directed genome editing. Compared to conventional plasmid-based expression vectors and donor templates, we show that combining RNP and AAV donor delivery increases the efficiency of gene addition by up to 12-fold, enabling the creation of lineage reporters that can be used to track the conversion of striatal neurons from human fibroblasts in real time. These results thus illustrate the potential for unifying nuclease protein delivery with AAV donor vectors for homology-directed genome editing.

1 May 2018 in Stem Cell Reports
Verified
Journal Article
Open access
MAMaroof M. Adil
Maroof M. Adil
TGThomas Gaj
Thomas Gaj
ARAntara T. Rao
Antara T. Rao
RKRishikesh U. Kulkarni
Rishikesh U. Kulkarni
CFChristina M. Fuentes
Christina M. Fuentes
DSDavid Schaffer
David Schaffer
Huntington disease (HD) is an inherited, progressive neurological disorder characterized by degenerating striatal medium spiny neurons (MSNs). One promising approach for treating HD is cell replacement therapy, where lost cells are replaced by MSN progenitors derived from human pluripotent stem cells (hPSCs). While there has been remarkable progress in generating hPSC-derived MSNs, current production methods rely on two-dimensional culture systems that can include poorly defined components, limit scalability, and yield differing preclinical results. To facilitate clinical translation, here, we generated striatal progenitors from hPSCs within a fully defined and scalable PNIPAAm-PEG three-dimensional (3D) hydrogel. Transplantation of 3D-derived striatal progenitors into a transgenic mouse model of HD slowed disease progression, improved motor coordination, and increased survival. In addition, the transplanted cells developed an MSN-like phenotype and formed synaptic connections with host cells. Our results illustrate the potential of scalable 3D biomaterials for generating striatal progenitors for HD cell therapy.

6 April 2026 in Research Square
Verified
Preprint
Open access
PDF file
MPMatthew Porteus
Matthew Porteus
SLSofia Luna
Sofia Luna
WFWilliam Feist
William Feist
AUAshley Utz
Ashley Utz
JAJumana Afaghani
Jumana Afaghani
LSLudwig Schmiderer
Ludwig Schmiderer
Monoclonal antibodies represent half of the top ten selling drugs. Their proven efficacy, however, generally requires repeated administration for prolonged periods of time. In contrast, cell-based therapies offer a different set of pharmacokinetics and pharmacodynamics than traditional medicines, including the potential to have lifetime durability after a single infusion. Here, we describe a genome-engineered stem cell-based platform for continuous antibody production from a single dose. Using CRISPR/Cas9 homology-directed repair mediated editing, we precisely integrated therapeutic antibody expression cassettes into a safe-harbor locus of hematopoietic stem and progenitor cells (HSPCs). Upon differentiation, these gene-targeted HSPCs generate B cells that secrete monoclonal antibodies. We validated this platform using two clinically approved antibodies, achieving efficient targeted integration of the gene-targeted antibodies (GT-Ab) in human HSPCs that successfully engraft in immunodeficient mice. Direct engineering of human B cells demonstrated robust secretion of therapeutic antibodies. To evaluate in vivo antibody production, we transplanted engineered GT-Ab murine HSPCs into immunocompetent mice, achieving durable serum antibody concentrations within the therapeutic range over several months. Lastly, by fusing the antibody to a destabilization domain, we enabled tunable antibody secretion via small molecule regulation. This modular platform establishes a potentially curative approach for chronic diseases currently reliant on repeated antibody administration, offering durable antibody production from a single treatment.

11 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSridhar Selvaraj
Sridhar Selvaraj
LSLudwig Schmiderer
Ludwig Schmiderer
JLJacob Lamberth
Jacob Lamberth
TFThomas Fuchss
Thomas Fuchss
FEFreja K. Ekman
Freja K. Ekman
MPMatthew H. Porteus
Matthew H. Porteus
Precise gene editing through homology directed repair (HDR) is one of the most versatile genome editing approaches with broad applications. Achieving high HDR gene editing efficiency is critical to realizing the full potential of this approach. Although many strategies have been explored to enhance HDR editing efficiency, inhibition of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a key component of the non-homologous end joining (NHEJ) pathway remains one of the most effective. Here we describe a novel, highly potent DNA-PKcs small molecule inhibitor, TFU72 which enhances HDR gene editing efficiency remarkably by up to 30-fold in cell lines and human primary cells. We assessed the previously reported genotoxic outcomes associated with DNA-PKcs inhibition such as off-target mutations, chromosomal translocations and large deletions and describe approaches to mitigate these outcomes to safely enhance HDR gene editing efficiency with TFU72. This optimized approach enables broad application of TFU72 for HDR-based precise gene editing applications in both therapeutic and research settings.